close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Numab Therapeutics AG

News headline image
Numab Therapeutics Achieves Milestone in Second Collaboration Project with Boehringer Ingelheim
From Numab Therapeutics AG
Via GlobeNewswire
News headline image
Numab Therapeutics and Kaken Pharmaceutical Announce Licensing and Co-development Agreement for Multispecific Antibody NM81 in Inflammatory Bowel Disease (IBD)
From Numab Therapeutics AG
Via GlobeNewswire
News headline image
Numab Therapeutics Achieves Milestone in Collaboration with Boehringer Ingelheim
From Numab Therapeutics AG
Via GlobeNewswire
News headline image
Numab Therapeutics Announces Leadership Transition and Appoints Angehrn Pavik as Chief Executive Officer
From Numab Therapeutics AG
Via GlobeNewswire
News headline image
Numab Therapeutics Announces Series C Extension to CHF 180 Million, Completing Oversubscribed CHF 50 Million Financing
From Numab Therapeutics AG
Via GlobeNewswire
News headline image
Numab Therapeutics Announces Initiation of Phase 1 Clinical Study of NM32 Program in Patients with Solid Tumors
From Numab Therapeutics AG
Via GlobeNewswire
News headline image
Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for the Treatment of Atopic Dermatitis
From Numab Therapeutics AG
Via GlobeNewswire
Tickers JNJ
News headline image
Numab Therapeutics and Ono Pharmaceutical Announce an Option and Collaboration Agreement to Develop Multi-specific Antibody NM49 for Treatment of Cancer
From Numab Therapeutics AG
Via GlobeNewswire
News headline image
Numab Therapeutics Announces First Patient Dosed in Phase 1 Multiple Ascending Dose (MAD) Study of NM26 for Moderate to Severe Atopic Dermatitis
From Numab Therapeutics AG
Via Business Wire
News headline image
Numab Therapeutics Announces First Subject Dosed in Phase 1 Clinical Study of NM26 Program
From Numab Therapeutics AG
Via Business Wire
News headline image
Numab Therapeutics and Ono Pharmaceutical Enter Development and License Agreement for Multispecific Antibody Candidate Involving Novel Immuno-Oncology Target
From Numab Therapeutics AG
Via Business Wire
News headline image
Numab and 3SBio’s Sunshine Guojian Expand Partnership to Develop Novel T Cell Engager NM28
From Numab Therapeutics AG
Via Business Wire
News headline image
Numab Therapeutics Completes Oversubscribed CHF 100 Million Series C Financing
From Numab Therapeutics AG
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today